GO:0010875 positive regulation of cholesterol efflux: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010875 describes any process that increases the frequency, rate or extent of cholesterol efflux, the directed movement of cholesterol out of a cell or organelle.
• ABCA1 is the central transporter that mediates cholesterol efflux to lipid-poor apolipoproteins, and its activity is regulated by signaling pathways such as sphingosine-1-phosphate.
• Cholesterol efflux is not only a lipid transport event; it reprograms immune cells, including macrophages, and influences tumor progression and immunotherapy responses [2,5,6,8].
• Multiple genes beyond ABCA1, such as SCARB1, APOE, and DOCK7, modulate efflux capacity and downstream phenotypes in cancer and inflammation [4,5].
• Dysregulated cholesterol efflux contributes to atherosclerosis, periodontitis, hepatocellular carcinoma, glioblastoma, and clear cell renal cell carcinoma [2,3,4,8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential to establish causal roles of efflux genes in disease.
Description
Cholesterol efflux is the directed movement of cholesterol out of a cell or organelle, and its positive regulation (GO:0010875) encompasses any process that increases the frequency, rate or extent of this transport. This biological process is fundamental to cellular lipid homeostasis and is best known for its role in reverse cholesterol transport, where peripheral cells export excess cholesterol to extracellular acceptors such as apolipoprotein A-I (APOA1) and high-density lipoprotein (HDL) particles. The ATP-binding cassette transporter ABCA1 is the rate-limiting facilitator of cholesterol efflux to lipid-poor apolipoproteins, and its expression and activity are tightly controlled by signaling pathways including sphingosine-1-phosphate (S1P) signaling in macrophages. Beyond its classical role in cardiovascular biology, positive regulation of cholesterol efflux has emerged as a critical modulator of immune cell function and cancer progression. For example, acceleration of HDL-mediated cholesterol efflux alleviates periodontitis in experimental models, while cholesterol efflux driven by tumor-associated macrophages promotes immunosuppression and hepatocellular carcinoma progression. In glioblastoma, modulation of cholesterol metabolism in glioma-supportive macrophages enhances postoperative immunotherapy. These findings position GO:0010875 as a nexus connecting lipid metabolism, inflammation, and tumor immunology. Researchers studying this process require reliable models to dissect the molecular players and regulatory mechanisms. CRISPR-based gene editing enables precise knockout, point mutation, knock-in, and overexpression of genes such as ABCA1, SCARB1, and APOE, allowing causal inference in relevant cell types. This article integrates authoritative QuickGO annotation with verified PubMed literature to provide a research-grade overview of positive regulation of cholesterol efflux, its key genes, disease relevance, and experimental strategies.
positive regulation of cholesterol efflux At A Glance
| GO ID | GO:0010875 |
|---|---|
| GO term | positive regulation of cholesterol efflux |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate or extent of cholesterol movement out of cells or organelles |
| Related process | Cholesterol efflux (GO:0033344) and regulation of cholesterol efflux (GO:0010874) |
| Key transporters | ABCA1, ABCG1, SCARB1 |
| Key acceptors | APOA1, HDL particles |
| Disease relevance | Atherosclerosis, cancer, periodontitis, metabolic disorders |
What Is GO:0010875?
GO:0010875, positive regulation of cholesterol efflux, is defined by QuickGO as any process that increases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux itself is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle. In practical terms, this GO term captures the upstream signals, transporters, and acceptor molecules that enhance the export of cholesterol from cells, as opposed to the basal efflux process or its negative regulation.
Why Is positive regulation of cholesterol efflux Important in Cell Biology?
Positive regulation of cholesterol efflux is critically important because it controls cellular cholesterol balance and influences systemic lipid metabolism, immune cell function, and disease outcomes. Impaired efflux leads to cholesterol accumulation in macrophages, a hallmark of atherosclerotic plaques, while enhanced efflux can alleviate inflammatory conditions such as periodontitis. In cancer, cholesterol efflux supports the generation of immunosuppressive macrophages that promote tumor progression, as shown in hepatocellular carcinoma and glioblastoma. Therefore, understanding how this process is regulated offers therapeutic opportunities across cardiovascular, inflammatory, and oncological diseases.
• Maintains cellular cholesterol homeostasis and prevents lipotoxicity.
• Mediates reverse cholesterol transport, a protective pathway against atherosclerosis.
• Regulates macrophage polarization and inflammatory responses [1,8].
• Supports anticancer functions of myeloid immune cells.
• Promotes immunosuppressive macrophage generation in hepatocellular carcinoma.
• Modulates postoperative glioblastoma immunotherapy responses.
• Alleviates periodontitis in preclinical models.
• Influences clear cell renal cell carcinoma progression via SCARB1 stabilization.
• Drives colorectal cancer metastasis through DOCK7-enriched extracellular vesicles.
• Provides a target for CRISPR-based functional genomics and drug discovery.
What Happens During positive regulation of cholesterol efflux?
Initiation by extracellular acceptors
In simple terms: Cholesterol needs a partner outside the cell to be carried away.
The process begins when lipid-poor apolipoproteins such as APOA1 or HDL particles interact with cell surface transporters. In macrophages, sphingosine-1-phosphate signaling regulates ABCA1-mediated cholesterol efflux, influencing the initial step of acceptor binding and cholesterol transfer. Acceleration of HDL-mediated cholesterol efflux has been shown to alleviate periodontitis, indicating that acceptor availability and function are rate-limiting for the positive regulation of efflux.
Transporter activation and cholesterol transfer
In simple terms: Transporter proteins on the cell membrane pump cholesterol out.
ABCA1 and other transporters facilitate the transfer of cholesterol from the plasma membrane to extracellular acceptors. The activity of ABCA1 is positively regulated by S1P signaling in macrophages. In clear cell renal cell carcinoma, circABCA1 promotes cholesterol metabolism reprogramming and M2 macrophage polarization through IGF2BP3-mediated stabilization of SCARB1 mRNA, linking transporter regulation to efflux capacity. DOCK7-enriched extracellular vesicles from tumor-associated macrophages drive metastasis via the RAC1/ABCA1 axis, further highlighting transporter regulation in efflux.
Downstream signaling and immune modulation
In simple terms: Efflux changes how immune cells behave.
Positive regulation of cholesterol efflux alters intracellular cholesterol pools that serve as signaling platforms. Cholesterol efflux drives the generation of immunosuppressive macrophages to promote hepatocellular carcinoma progression. In glioblastoma, intracavitary spraying of a nanoregulator-encased hydrogel modulates cholesterol metabolism of glioma-supportive macrophages, enhancing postoperative immunotherapy. ABCA1 supports anticancer functions of myeloid immune cells, demonstrating that efflux proteins can have context-dependent roles in tumor immunity.
Systemic consequences and disease modification
In simple terms: What happens in cells affects the whole body.
Enhanced cholesterol efflux can alleviate inflammatory diseases such as periodontitis. Conversely, dysregulated efflux contributes to cancer progression and metastasis, as seen in colorectal cancer where DOCK7-enriched extracellular vesicles drive metastasis via the RAC1/ABCA1 axis. These systemic effects underscore the importance of understanding positive regulation of cholesterol efflux in multiple disease contexts.
Key Genes Involved in GO:0010875 positive regulation of cholesterol efflux
The following genes and proteins are central to the positive regulation of cholesterol efflux, based on verified literature and their established roles in lipid transport and immune modulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCA1 | ATP-binding cassette transporter mediating cholesterol efflux to APOA1 | Rate-limiting transporter; regulated by S1P signaling; supports anticancer myeloid functions |
| ABCG1 | Transporter facilitating cholesterol efflux to HDL | Complementary to ABCA1 in macrophage efflux |
| SCARB1 | Scavenger receptor class B member 1; binds HDL and mediates selective cholesterol uptake and efflux | Stabilized by IGF2BP3 in ccRCC; promotes M2 polarization |
| APOA1 | Major apolipoprotein acceptor for ABCA1-mediated efflux | Key component of HDL; used in efflux assays |
| APOE | Apolipoprotein involved in cholesterol transport and efflux | Modulates efflux in macrophages and brain |
| DOCK7 | Guanine nucleotide exchange factor; enriched in extracellular vesicles | Drives metastasis via RAC1/ABCA1 axis in colorectal cancer |
| RAC1 | Small GTPase regulating actin dynamics and transporter trafficking | Mediates DOCK7 effects on ABCA1 and metastasis |
| IGF2BP3 | RNA-binding protein stabilizing SCARB1 mRNA | Promotes ccRCC progression and M2 polarization |
| S1PR1 | Sphingosine-1-phosphate receptor 1 | Regulates ABCA1-mediated efflux in macrophages |
| SPHK1 | Sphingosine kinase 1; produces S1P | Upstream of S1P signaling that regulates efflux |
| NR1H2 | Liver X receptor beta; transcription factor | Induces ABCA1 and ABCG1 expression |
| NR1H3 | Liver X receptor alpha; transcription factor | Master regulator of cholesterol efflux genes |
| PPARG | Peroxisome proliferator-activated receptor gamma | Promotes efflux in macrophages |
| STAT1 | Signal transducer and activator of transcription 1 | Modulates immune cell cholesterol metabolism |
| IL10 | Interleukin 10; anti-inflammatory cytokine | Associated with immunosuppressive macrophage phenotype driven by efflux |
| TGFB1 | Transforming growth factor beta 1 | Linked to efflux-driven immunosuppression |
| CCL2 | Chemokine ligand 2 | Recruits macrophages in efflux-related inflammation |
| HIF1A | Hypoxia-inducible factor 1 alpha | Regulates cholesterol metabolism in glioblastoma microenvironment |
How Is positive regulation of cholesterol efflux Regulated?
Positive regulation of cholesterol efflux is controlled at multiple levels. Transcriptional regulation via liver X receptors (NR1H2/NR1H3) induces ABCA1 and ABCG1 expression in response to cholesterol loading. Post-translational regulation includes sphingosine-1-phosphate signaling, which enhances ABCA1-mediated efflux in macrophages. In cancer, circABCA1 promotes cholesterol metabolism reprogramming through IGF2BP3-mediated stabilization of SCARB1 mRNA, increasing efflux capacity. DOCK7-enriched extracellular vesicles from tumor-associated macrophages activate RAC1 to regulate ABCA1 and drive metastasis. Additionally, cholesterol efflux itself drives the generation of immunosuppressive macrophages in hepatocellular carcinoma, indicating a feed-forward regulatory loop. These layers of regulation ensure that efflux is adaptive to cellular lipid status and microenvironmental cues.
positive regulation of cholesterol efflux and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCA1 | Atherosclerosis, cancer immunity | Macrophage-specific KO; overexpression in cancer cells |
| SCARB1 | Clear cell renal cell carcinoma | Knockout in ccRCC cell lines; mRNA stabilization assays |
| DOCK7 | Colorectal cancer metastasis | Knockout in macrophages; extracellular vesicle transfer models |
| ABCA1 | Periodontitis | Oral epithelial cells; HDL-mediated efflux assays |
| ABCA1 | Glioblastoma immunotherapy | Glioma-supportive macrophage co-culture; hydrogel delivery models |
Cancer progression and immunotherapy
Cholesterol efflux promotes immunosuppressive macrophage phenotypes that support tumor growth. In hepatocellular carcinoma, cholesterol efflux drives the generation of immunosuppressive macrophages to promote progression. In glioblastoma, modulating cholesterol metabolism of glioma-supportive macrophages via a nanoregulator-encased hydrogel enhances postoperative immunotherapy. ABCA1 supports anticancer functions of myeloid immune cells, suggesting context-dependent roles. In clear cell renal cell carcinoma, circABCA1 promotes progression by reprogramming cholesterol metabolism and facilitating M2 macrophage polarization through IGF2BP3-mediated stabilization of SCARB1 mRNA. Colorectal cancer metastasis is driven by DOCK7-enriched extracellular vesicles via the RAC1/ABCA1 axis.
Inflammatory and periodontal disease
Acceleration of HDL-mediated cholesterol efflux alleviates periodontitis, indicating that enhancing efflux can reduce inflammatory pathology. This aligns with the broader anti-inflammatory role of reverse cholesterol transport.
Cardiometabolic disease
Cholesterol efflux is a protective mechanism against atherosclerosis, and clinical trials have explored therapeutic strategies to enhance efflux. Although specific trial results are beyond the scope of this article, the pathway remains a major target for cardiovascular drug development.
From positive regulation of cholesterol efflux-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ABCA1 reduce cholesterol efflux? | ABCA1 knockout cell line (e.g., macrophages) |
| Does a point mutation in ABCA1 affect transporter function? | Point-mutation knock-in via CRISPR |
| Does overexpression of SCARB1 increase efflux and M2 polarization? | SCARB1 overexpression in ccRCC cells |
| Does tagging ABCA1 alter its trafficking? | Tagged knock-in (e.g., GFP-ABCA1) |
| Does DOCK7 in extracellular vesicles regulate ABCA1 in recipient cells? | DOCK7 knockout donor cells; EV transfer to wild-type recipients |
| Does cholesterol efflux modulate immunotherapy response? | Syngeneic tumor models with macrophage-specific gene editing |
How to Study the positive regulation of cholesterol efflux Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cholesterol efflux assay | Rate of cholesterol transfer to acceptors | Functional validation of ABCA1/SCARB1 perturbations |
| RNA-seq | Transcriptional changes in efflux genes | Pathway analysis in disease models |
| RIP-seq | RNA-protein interactions | Identifying IGF2BP3 targets like SCARB1 |
| Extracellular vesicle characterization | Vesicle protein cargo and size | Studying DOCK7-mediated intercellular communication |
| Immunoblotting | Protein expression and phosphorylation | Assessing ABCA1 levels and RAC1 activation |
| Flow cytometry | Macrophage polarization markers | Evaluating M2 polarization after efflux modulation [4,8] |
| CRISPR screening | Gene essentiality or efflux regulators | Unbiased discovery of efflux modulators |
| In vivo tumor growth | Tumor progression and survival | Testing efflux-targeted immunotherapy [2,8] |
Cholesterol efflux assays
Radiolabeled or fluorescent cholesterol efflux assays measure the transfer of cholesterol from cells to extracellular acceptors such as APOA1 or HDL. These assays are used to quantify the functional impact of genetic perturbations in ABCA1, SCARB1, and other genes [1,3].
Gene expression and RNA-binding protein analysis
Quantitative PCR, RNA-seq, and RNA immunoprecipitation (RIP) can assess expression of efflux genes and mRNA stability. For example, IGF2BP3-mediated stabilization of SCARB1 mRNA was demonstrated using such approaches.
Extracellular vesicle isolation and functional transfer
Extracellular vesicles can be isolated from conditioned media and characterized for protein content such as DOCK7. Transfer experiments to recipient cells followed by efflux measurement reveal intercellular regulation.
In vivo tumor models and immunotherapy
Syngeneic or xenograft tumor models combined with macrophage-specific gene editing or nanoregulator delivery can test the impact of cholesterol efflux on tumor growth and immunotherapy response [2,8].
How CRISPR Can Be Used to Study GO:0010875 positive regulation of cholesterol efflux
Knockout
CRISPR knockout of ABCA1, SCARB1, or DOCK7 in relevant cell types (e.g., macrophages, cancer cells) abolishes or reduces cholesterol efflux, enabling causal tests of gene function. For example, ABCA1 knockout macrophages show impaired efflux to APOA1.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to dissect functional domains of transporters. For instance, mutating phosphorylation sites in ABCA1 can reveal regulatory mechanisms.
Knock-in
Knock-in of tagged versions (e.g., GFP-ABCA1) allows real-time tracking of transporter localization and trafficking. Knock-in of human disease variants into mouse models can reproduce efflux defects.
Overexpression
Overexpression of ABCA1 or SCARB1 increases cholesterol efflux capacity and can drive phenotypic changes such as M2 macrophage polarization. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports positive regulation of cholesterol efflux Research
Researchers studying positive regulation of cholesterol efflux-related genes often need to determine whether a candidate gene is causally involved in efflux regulation or simply correlated with the phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal inference, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cholesterol efflux research.
Frequently Asked Questions About positive regulation of cholesterol efflux
What is GO:0010875?
GO:0010875 is the Gene Ontology term for positive regulation of cholesterol efflux, defined as any process that increases the frequency, rate or extent of cholesterol efflux, the directed movement of cholesterol out of a cell or organelle.
What genes are involved in positive regulation of cholesterol efflux?
Key genes include ABCA1, ABCG1, SCARB1, APOA1, APOE, DOCK7, RAC1, and IGF2BP3, among others [1,4,5].
How is cholesterol efflux regulated?
Cholesterol efflux is regulated transcriptionally by liver X receptors, post-translationally by sphingosine-1-phosphate signaling, and through RNA stability mechanisms involving IGF2BP3 [1,4].
What diseases are associated with cholesterol efflux?
Diseases include atherosclerosis, periodontitis, hepatocellular carcinoma, glioblastoma, clear cell renal cell carcinoma, and colorectal cancer metastasis [2,3,4,5,8].
What is the role of ABCA1 in cholesterol efflux?
ABCA1 is the rate-limiting transporter that mediates cholesterol efflux to lipid-poor apolipoproteins such as APOA1, and its activity is regulated by S1P signaling.
How can I study positive regulation of cholesterol efflux using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to test the causal role of specific genes in efflux regulation.
What cell models are used for cholesterol efflux research?
Common models include macrophages, hepatocytes, cancer cell lines, and primary cells, often with HDL or APOA1 as acceptors [1,3].
Does cholesterol efflux affect cancer immunotherapy?
Yes, cholesterol efflux can drive immunosuppressive macrophage generation and modulate immunotherapy responses in glioblastoma and hepatocellular carcinoma [2,8].
What is the relationship between cholesterol efflux and periodontitis?
Acceleration of HDL-mediated cholesterol efflux alleviates periodontitis in experimental models.
How does DOCK7 regulate cholesterol efflux?
DOCK7-enriched extracellular vesicles from tumor-associated macrophages drive metastasis via the RAC1/ABCA1 axis, modulating cholesterol efflux.
Conclusion
Positive regulation of cholesterol efflux (GO:0010875) is a fundamental biological process with far-reaching implications for cardiovascular health, inflammation, and cancer. The interplay between transporters like ABCA1, acceptors like APOA1, and regulatory signaling pathways such as S1P determines the efficiency of cholesterol export and its downstream effects on immune cells and tumor progression. CRISPR-based models are indispensable for dissecting these mechanisms and identifying therapeutic targets. EDITGENE offers comprehensive services to support such research, from gene knockout to library screening and bioinformatics.
References
- 1. Vaidya M et al.. 2019. Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages.. J Lipid Res 60(3):506-515 PMID: 30655318
- 2. Dong Y et al.. 2024. Intracavitary Spraying of Nanoregulator-Encased Hydrogel Modulates Cholesterol Metabolism of Glioma-Supportive Macrophage for Postoperative Glioblastoma Immunotherapy.. Adv Mater 36(13):e2311109 PMID: 38127403
- 3. Tran TT et al.. 2024. Acceleration of HDL-Mediated Cholesterol Efflux Alleviates Periodontitis.. J Dent Res 103(11):1109-1118 PMID: 39311443
- 4. Ning H et al.. 2025. CircABCA1 promotes ccRCC by reprogramming cholesterol metabolism and facilitating M2 macrophage polarization through IGF2BP3-mediated stabilization of SCARB1 mRNA.. Mol Cancer 24(1):199 PMID: 40684174
- 5. Chen W et al.. 2024. Tumour-associated macrophage-derived DOCK7-enriched extracellular vesicles drive tumour metastasis in colorectal cancer via the RAC1/ABCA1 axis.. Clin Transl Med 14(2):e1591 PMID: 38385857
- 6. Bendre SV et al.. 2026. Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells.. Sci Adv 12(1):eadx5490 PMID: 41477845
- 7. Horowitz JD et al.. 2011. Clinical Trials Update AHA Congress 2010.. Cardiovasc Drugs Ther 25(1):69-76 PMID: 21340529
- 8. Li Z et al.. 2023. Cholesterol Efflux Drives the Generation of Immunosuppressive Macrophages to Promote the Progression of Human Hepatocellular Carcinoma.. Cancer Immunol Res 11(10):1400-1413 PMID: 37467346
